[go: up one dir, main page]

AU7360000A - Methods and compositions for preventing and treating prostate disorders - Google Patents

Methods and compositions for preventing and treating prostate disorders

Info

Publication number
AU7360000A
AU7360000A AU73600/00A AU7360000A AU7360000A AU 7360000 A AU7360000 A AU 7360000A AU 73600/00 A AU73600/00 A AU 73600/00A AU 7360000 A AU7360000 A AU 7360000A AU 7360000 A AU7360000 A AU 7360000A
Authority
AU
Australia
Prior art keywords
compositions
preventing
methods
treating prostate
prostate disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU73600/00A
Inventor
Gary W. Neal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Androsolutions Inc
Original Assignee
Androsolutions Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Androsolutions Inc filed Critical Androsolutions Inc
Publication of AU7360000A publication Critical patent/AU7360000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/08—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of suppositories or sticks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
AU73600/00A 1999-09-09 2000-09-08 Methods and compositions for preventing and treating prostate disorders Abandoned AU7360000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15290299P 1999-09-09 1999-09-09
US60152902 1999-09-09
PCT/US2000/024676 WO2001017479A2 (en) 1999-09-09 2000-09-08 Methods and compositions for preventing and treating prostate disorders

Publications (1)

Publication Number Publication Date
AU7360000A true AU7360000A (en) 2001-04-10

Family

ID=22544943

Family Applications (2)

Application Number Title Priority Date Filing Date
AU73600/00A Abandoned AU7360000A (en) 1999-09-09 2000-09-08 Methods and compositions for preventing and treating prostate disorders
AU73607/00A Abandoned AU7360700A (en) 1999-09-09 2000-09-08 Methods and compositions for preventing and treating urinary tract disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU73607/00A Abandoned AU7360700A (en) 1999-09-09 2000-09-08 Methods and compositions for preventing and treating urinary tract disorders

Country Status (3)

Country Link
EP (2) EP1214039A2 (en)
AU (2) AU7360000A (en)
WO (2) WO2001017480A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099003A1 (en) 1997-10-28 2002-07-25 Wilson Leland F. Treatment of female sexual dysfunction with vasoactive agents, particularly vasoactive intestinal polypeptide and agonists thereof
GB0029903D0 (en) * 2000-12-07 2001-01-24 Arakis Ltd Use of anti-muscarinic agents
DE10103262A1 (en) * 2001-01-25 2002-08-01 Axel Schmidt-Dossi Suppository containing oxybutynin, useful for treatment of incontinence, avoids side effects and allows an increase in dose
TWI301164B (en) * 2001-10-12 2008-09-21 Phild Co Ltd
FR2850864B1 (en) * 2003-02-12 2007-04-13 Oreal USE OF A 15-HYDROXY PROSTAGLANDIN DEHYDROGENASE INHIBITOR TO PROMOTE PIGMENTATION OF SKIN OR PHANES
WO2004073594A2 (en) * 2003-02-12 2004-09-02 L'oreal Use of an inhibitor of 15-hydroxyprostaglandin dehydrogenase in order to stimulate pigmentation of the skin or skin appendages
ATE427108T1 (en) * 2004-08-11 2009-04-15 Boehringer Ingelheim Pharma MEDICINAL PRODUCTS CONTAINING ANTICHOLINERGICS FOR THE TREATMENT OF DISEASES OF THE URINARY TRACT
US20090186896A1 (en) * 2005-09-29 2009-07-23 Bayer Healthcare Ag PDE Inhibitors and Combinations Thereof for the Treatment of Urological Disorders
US7902260B2 (en) 2007-02-28 2011-03-08 Kemphys Ltd. Medicament for preventive and/or therapeutic treatment of lower urinary tract symptom
US9415048B2 (en) 2010-07-08 2016-08-16 Wellesley Pharmaceuticals, Llc Pharmaceutical formulation for reducing frequency of urination and method of use thereof
US10278925B2 (en) 2012-01-04 2019-05-07 Wellesley Pharmaceuticals, Llc Delayed-release formulations, methods of making and use thereof
WO2013103389A1 (en) 2012-01-04 2013-07-11 Wellesley Pharmaceuticals, Llc Delayed-release formulation for reducing the frequency of urination and method of use thereof
AU2013293488B2 (en) * 2012-07-27 2018-05-17 David A. Dill Pharmaceutical formulation for reducing frequency of urination and method of use thereof
CA2979203A1 (en) * 2015-03-08 2016-09-15 Case Western Reserve University Inhibitors of short-chain dehydrogenase activity for treating fibrosis
US11690847B2 (en) 2016-11-30 2023-07-04 Case Western Reserve University Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof
JP2020514323A (en) 2017-02-06 2020-05-21 ケース ウエスタン リザーブ ユニバーシティ Compositions and methods for modulating short chain dehydrogenase activity
IL296845A (en) 2020-03-30 2022-11-01 Trizell Ltd Preparations and methods for the treatment of cancer

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3171774D1 (en) * 1980-03-31 1985-09-19 Teijin Ltd Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom
US4474813A (en) * 1980-10-24 1984-10-02 Schering Corporation Pharmaceutical preparations comprising flutamide
SU1130345A1 (en) * 1981-12-10 1984-12-23 Киевский Научно-Исследовательский Институт Заболеваний Почек И Мочевыводящих Путей /Урологии/ Method of treatment of chronic urethroprostatitis
DE3408260A1 (en) * 1984-03-07 1985-09-26 Roshdy Dipl.-Chem. Dr. 5000 Köln Ismail Suppositories containing vitamin E
US5085650A (en) * 1989-10-20 1992-02-04 Giglio Frank A Gynecological urethral suppository
CN1030687C (en) * 1989-11-17 1996-01-17 沈阳铁路局中心医院 Preparation method of urethra administration dosage form
RU2024253C1 (en) * 1991-03-27 1994-12-15 Валентина Васильевна Малиновская Rectal suppositories and device for introduction thereof
GB2260902A (en) * 1991-09-12 1993-05-05 Eurocetus Bv Interleukin-2 and tumour necrosis factor for treating bladder cancer
US5598549A (en) * 1993-06-11 1997-01-28 At&T Global Information Solutions Company Array storage system for returning an I/O complete signal to a virtual I/O daemon that is separated from software array driver and physical device driver
US5480640A (en) * 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
DE19529102A1 (en) * 1995-08-08 1997-02-13 Kummer Horst Dieter Use of PDE inhibitors in the treatment of bladder disorders
AU7130696A (en) * 1995-09-19 1997-04-09 Schering Aktiengesellschaft Combination of beta-interferon for the treatment of prostate cancer
DE19540642A1 (en) * 1995-11-01 1997-05-07 Stief Christian Georg Priv Doz Use of phosphodiesterase I, IV and V inhibitors
US5877215A (en) * 1996-03-20 1999-03-02 Medical University Of South Carolina Method of treating neoplastic cells with prostaglandin and radiation treatment or prostaglandin and platinum-based anti-tumor agents
CA2650204A1 (en) * 1996-12-31 1998-07-09 Harry B. Demopoulos Pharmaceutical preparations of glutathione and methods of administration thereof
KR20010021625A (en) * 1997-07-09 2001-03-15 추후보정 Improved Methods and Compositions for Treating Male Erectile Dysfunction
US6630515B2 (en) * 1997-08-28 2003-10-07 Afferon Corporation Urinary incontinence therapy
DE19739693A1 (en) * 1997-09-04 1999-03-11 Schering Ag Synergistic treatment of multiple sclerosis and other neurodegenerative disorders
DE1003496T1 (en) * 1998-05-07 2000-11-02 Univ Tennessee Res Corp Method of preventing prostate cancer

Also Published As

Publication number Publication date
WO2001017479A2 (en) 2001-03-15
WO2001017479A3 (en) 2001-09-20
AU7360700A (en) 2001-04-10
EP1214039A2 (en) 2002-06-19
WO2001017479B1 (en) 2002-02-07
WO2001017480A3 (en) 2001-11-01
EP1214038A2 (en) 2002-06-19
WO2001017480A2 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
AU8003800A (en) Methods and compositions for treating neurobehavioral disorders
HUP0201436A2 (en) Methods and compositions for treating solid tumors
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
AU2212299A (en) Compositions and methods for the treatment of tumor
AU1296099A (en) Methods and compositions for treating dermatoses
AU7604400A (en) Methods and compositions for treating platelet-related disorders using mpl pathway inhibitory agents
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AUPQ127399A0 (en) Compositions and methods for treating or preventing osteoporosis
AU3877900A (en) Compositions and methods for preventing and treating sexual dysfunctions
AU7360000A (en) Methods and compositions for preventing and treating prostate disorders
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
AU5601300A (en) Method and compositions for treating and preventing retinal damage
AU3086900A (en) Device for the complex treatment of disorders of the prostate
AU2002236626A1 (en) Compositions and methods for treating hyperpigmentation
AU1359801A (en) Methods and compositions for treating reward deficiency syndrome
AU5838700A (en) Method for treating and preventing finger disorders
AU5042000A (en) Methods of treating proliferative disorders
AU4033900A (en) Compositions and methods for treating cell proliferation disorders
AU2001218024A1 (en) Methods for treating and preventing alopecia
AUPQ872800A0 (en) Compositions and methods for treating cardiovascular disorders
AU3753500A (en) Methods of treating fibrinogen-related disorders
AU5097099A (en) Methods and compositions for cancer treatment

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase